Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
ASCO 2024 preview – two strikes against USP1
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
Merck KGaA’s oncology catalyst approaches
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.
Finding the USP in synthetic lethality
A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.
